The Pharmasyntez Group of Companies is proud to announce the approval of the first generic version of the Epclusa combination antiviral medicine, which contains the active ingredients Velpatasvir and Sofosbuvir. The new drug named Velpatasof is intended for the treatment of chronic hepatitis C.

Velpatasof is recommended for use in adults and children over 12 years of age with a body weight of at least 30 kg. The medication is produced in the form of film-coated tablets with a 100 mg + 400 mg fixed strength. The medication is included in the Clinical Recommendations for the treatment of chronic hepatitis C and in the List of Vital and Essential drugs. Velpatasof is effective against all viral hepatitis C genotypes.

Velpatasof and other direct antivirals with a pangenotypic mechanism of action are the most popular option for treating chronic HCV infection, providing a short course of treatment (8 to 12 weeks), which increases patient compliance. In addition, these medicines have a low incidence of adverse events and are very effective in the treatment of chronic hepatitis C. Velpatasof can also be used in retreatment regimens for patients who have relapsed after primary treatment failed, as well as in patients with concurrent diseases.

Pharmasyntez JSC is still committed to helping patients live better lives by offering affordable and efficient treatments for viral infections.